Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients

4. august 2018 oppdatert av: HuKe, Renmin Hospital of Wuhan University
This study mainly focused on the effect of early antiviral treatment on the duration of cough in influenza patients.investigators conducted an early investigation of patients with positive influenza virus and asked whether patients used antiviral drugs in the early stages. According to the use of drugs, patients were divided into oral oseltamivir group, oral lotus phlegm group and other groups, and investigators will collected Inspection information and medication status,during the treatment period of patients.

Studieoversikt

Status

Ukjent

Detaljert beskrivelse

Cough is a common symptom of respiratory diseases and helps to clear respiratory secretions and harmful factors, but frequent severe coughing has a serious impact on the patient's work, life and social activities. Upper respiratory tract viral infection is a common cause of coughing. Many patients have a long duration of cough after suffering from flu. Cough can last for several weeks, and most often have irritating dry cough or a small amount of white mucus sputum. This type of cough is also often referred to as "subacute cough" or "post-infection cough." The mechanisms that cause this cough have not been fully elucidated, and the effect of conventional treatment is not good, and chest imaging has no obvious abnormalities. The use of large amounts of antibiotics is ineffective or ineffective. Antihistamine H1 receptor antagonists and central antitussives are often only effective or ineffective in the short term. The effects of various bronchodilators and even hormone drugs are not clear. Due to the poor efficacy of multiple treatments, patients are repeatedly subjected to various tests, which not only increases the pain but also aggravates the economic burden.

Therefore, it is necessary to further clarify the causes and treatment measures of post-influenza cough patients.

Studietype

Observasjonsmessig

Registrering (Forventet)

120

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Hubei
      • Wuhan, Hubei, Kina, 430060
        • Renmin Hospital of Wuhan University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Flu patients who were diagnosed in our hospital from April 2018 to July 2019

Beskrivelse

Inclusion Criteria:

For patients with flu-free flu, cough for at least one week.

  1. In line with the flu etiological diagnostic criteria: According to the guidelines set by the National Health and Health Committee, the diagnosis is based on etiological screening methods or confirmed methods; ages 18 to 70 years.
  2. There are no influenza complications such as acute lower respiratory tract infection, tonsillitis, sinusitis, otitis media, myocarditis, etc.
  3. It is usually healthy and there are no chronic underlying diseases such as hypertension and diabetes.
  4. Treating with cough as the main symptom, the cough lasts for at least one week and the chest radiograph is normal.
  5. Signed informed consent.

Exclusion Criteria:

  1. Suspected flu patients who have not received the flu etiology test;
  2. There is a clear comorbid disease (combined with other sites of acute bacterial or viral infections);
  3. There is a clear cough caused by other reasons;
  4. With severe liver and kidney dysfunction;
  5. Pregnant women.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Oral oseltamivir group
Patients with influenza virus positive and early oral oseltamivir capsules
Oral Lotus Capsules group
Patients with positive influenza virus and early oral administration of lotus extract capsules
other group
Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cough duration
Tidsramme: 6 months
Investigators will follow up every other week for follow-up calls or outpatients to ask about cough and medication, until the patient stops coughing, cough lasts from 1 day to 12 weeks, and cough time is greater than 12 weeks. Investigators should seriously exclude cough caused by other factors. No other factors are still included in the study, and the maximum time is no more than 6 months. If there are other factors causing cough, it will not be included in the study.
6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Forventet)

1. september 2018

Primær fullføring (Forventet)

1. september 2019

Studiet fullført (Forventet)

1. desember 2019

Datoer for studieregistrering

Først innsendt

4. juli 2018

Først innsendt som oppfylte QC-kriteriene

4. august 2018

Først lagt ut (Faktiske)

7. august 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

7. august 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. august 2018

Sist bekreftet

1. juli 2018

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Influensavirusinfeksjon

3
Abonnere